Local anaesthetic shows promise in blocking childhood cancer spread, study finds
A drug best known for numbing the skin before minor medical procedures may hold unexpected promise in tackling one of the most aggressive childhood cancers. Researchers investigating neuroblastoma – a […]
Anthony Nolan and GOSH Charity launch “UK-first” research study to transform lives of children receiving cell therapy
Stem cell charity Anthony Nolan, in partnership with Great Ormond Street Hospital Charity (GOSH Charity), has launched a UK-first research project to improve the supportive care of children and young […]
Study offers clues to blood cancer risk, revealing how gene mutations compete over time
Researchers at Barts Cancer Institute, Queen Mary University of London, have developed a new way to understand how genetic changes linked to blood cancer evolve in our cells and why most people […]
Hundreds of patients to benefit from ‘two-minute’ cancer treatment
Patients in East Yorkshire and Northern Lincolnshire are to benefit from a formulation of a drug that is used in the treatment of 14 different types of cancer. Humber Health […]
UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies
UCB, a global biopharmaceutical company, has announced a new multi‑project strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons. The collaboration will unite Cancer Research UK’s […]
SMC recommends combination metastatic bladder cancer therapy following strong clinical trial outcomes
Scottish medicines consortium (SMC) is recommending the reimbursement of PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.1,2 Bladder cancer is […]
RYBREVANT®▼ (amivantamab) with LAZCLUZE™▼ (lazertinib) is accepted for use within NHS Scotland as a first-line treatment for adult patients with untreated advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations
Johnson & Johnson welcomes the decision made today by the Scottish Medicines Consortium (SMC) to accept RYBREVANT®▼ (amivantamab) with LAZCLUZE™▼ (lazertinib), for use within the National Health Service (NHS) Scotland […]
Delivering the National Cancer Plan into reality: Greetings from West Yorkshire and Harrogate and seven learnings from Denmark
In the following article, Jason Pawluk, Managing Director of West Yorkshire and Harrogate Cancer Alliance, examines the National Cancer Plan. The National Cancer Plan has been broadly welcomed as creating […]
Royal United Hospitals Bath brings cancer care closer to home for Frome and neighbouring community
People in Frome and the surrounding area can now access cancer care closer to home, thanks to a new satellite clinic run by the Royal United Hospitals Bath NHS Foundation […]
NICE issues Final Draft Guidance recommending that RYBREVANT®▼(amivantamab) with carboplatin and pemetrexed can be used during a managed access period for untreated advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adult
Johnson & Johnson is pleased to announce today that the National Institute for Health and Care Excellence (NICE) has recommended that RYBREVANT®▼ (amivantamab) with carboplatin and pemetrexed can be used […]
